InMode Ltd. reports developments in medical-technology devices that use radiofrequency technology for minimally invasive and non-invasive aesthetic and medical procedures. Company updates commonly address product platforms and treatment categories for plastic surgery, dermatology, gynecology, otolaryngology and ophthalmology, including face and body contouring, medical aesthetics and women's health.
Recurring news also covers GAAP and non-GAAP financial results, consumables and service revenue, regional performance in the United States and Europe, margin trends, investor-conference participation, board-reviewed strategic matters and capital allocation actions such as ordinary-share repurchase programs.
InMode (Nasdaq: INMD) will participate in the 13th Annual BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference in Snowbird, UT. Yair Malca, Chief Financial Officer, will host investor meetings on Wednesday, February 11, 2026. Interested investors should contact their BTIG salesperson to schedule a meeting and may visit InMode's investor relations site for event details.
InMode (NASDAQ: INMD) said it is aware of market speculation, including a non-binding proposal by Steel Partners to acquire 51% of outstanding shares, and confirmed it is evaluating strategic alternatives.
The company formed an independent directors' committee, retained independent legal and financial advisors, and said there is no assurance a transaction will occur or on timing or terms.
Steel Partners Holdings offered to buy 51% of InMode (NASDAQ: INMD) at $18.00 per share, a 29% premium to the unaffected January 23, 2026 price. Steel says the offer is fully funded with no financing contingency and cites weak TSR, high cash balances, and repeated guidance cuts.
InMode (Nasdaq: INMD) expects to release fourth-quarter and full-year 2025 results before market open on February 10, 2026 and will hold a conference call the same day at 8:30 a.m. ET. Management provided preliminary, subject-to-adjustment ranges: Q4 2025 revenue $103.6M–$103.8M; FY2025 revenue $370.2M–$370.4M; FY2025 non-GAAP gross margin 78%–79%. The company also provided FY2026 revenue guidance $365M–$375M. Speakers will include CEO Moshe Mizrahy, CFO Yair Malca and CTO Michael Kreindel. A live webcast and replay will be available; preregistration is offered for dial-in access.
InMode (NASDAQ: INMD) reported Q3 2025 GAAP revenue of $93.2M, down from $130.2M in Q3 2024 (which included $31.9M of pre-order sales). GAAP and non-GAAP gross margin was 78%. GAAP net income was $21.9M ($0.34 diluted EPS) and non-GAAP net income was $24.5M ($0.38 diluted EPS). Cash and marketable securities totaled $532.3M as of September 30, 2025. Management reaffirmed full‑year 2025 guidance: revenues of $365M–$375M, non‑GAAP gross margin 78%–80%, non‑GAAP operating income $93M–$98M, and non‑GAAP EPS $1.55–$1.59. Company noted cautious consumer demand and named Michael Dennison president of North America.
InMode (Nasdaq: INMD) appointed Michael Dennison as President of North America, effective Nov. 3, 2025. Dennison joins the role after nearly a decade at InMode and promotion from Vice President of Sales. The company said he progressed through roles from District Sales Manager to VP of Sales, driving national revenue growth, expanding market share, and strengthening distribution across North America.
Management said the move is part of a North American restructuring intended to advance strategic initiatives and accelerate growth. Dennison previously held multiple leadership positions at Cynosure and is described as having consistently exceeded sales targets and built high-performing teams.
InMode (Nasdaq: INMD) will participate in three investor conferences in November 2025: the UBS Global Healthcare Conference (in-person one-on-ones, Palm Beach Gardens, FL) on Monday, November 10; the Jefferies Global Healthcare Conference (in-person fireside chat and one-on-ones, London, U.K.) with a fireside chat at 4:00 pm GMT on Tuesday, November 18 and a live webcast available; and the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum (in-person one-on-ones, New York, NY) on Thursday, November 20. Presenters include CEO Moshe Mizrahy and CFO Yair Malca.
InMode (Nasdaq: INMD) expects to release Q3 2025 results before market open on Nov 5, 2025 and will host a conference call at 8:30 a.m. ET that day. Management currently expects Q3 revenue of $92.5M–$93.0M, a non-GAAP gross margin of 77%–79%, and reiterated full‑year 2025 revenue guidance of $365M–$375M. Preliminary results exclude share‑based compensation per the company’s non‑GAAP disclosure and remain subject to final adjustments. The company provided webcast, preregistration, and replay details for investors and analysts.
DOMA Perpetual Capital Management, a significant shareholder of InMode Ltd. (NYSE: INMD), has sent a letter to the company's Board of Directors urging for immediate capital return to shareholders. The activist investor is pushing for two major share buybacks: 10% in Q4 2025 and another 10% in Q1 2026.
The letter criticizes InMode's management, highlighting that the company holds 53% of its market cap ($510 million) in cash with no debt, while generating over 10% of its market cap in cash annually. DOMA argues that after subtracting the cash position, InMode trades at just 3x future free cash flow and earnings, representing a severely depressed valuation.
DOMA challenges management's anti-buyback stance and reminds the Board of its legal and fiduciary duties to shareholders, warning of potential legal consequences for failing to act in shareholders' best interests.
InMode (NASDAQ:INMD), a leading provider of innovative medical technologies, has announced its participation in the upcoming Baird 2025 Global Healthcare Conference. The company's CFO Yair Malca will engage in a fireside chat on September 10, 2025, at 8:30 AM ET in New York.
The presentation will be moderated by Baird's Senior Research Analyst Jeff Johnson and will be available via live webcast. Additionally, the company will conduct one-on-one meetings with investors during the conference.